Key result
Perindopril reduces adrenaline-induced platelet aggregation from baseline in patients with essential hypertension.
Why the study?
Does perindopril improve endothelial and platelet functions in patients with essential hypertension?
Does perindopril improve endothelial and platelet functions in patients with essential hypertension?
p-value: p=<0.02
Perindopril therapy for 1 month reduces adrenaline-induced platelet aggregation in patients with essential hypertension, suggesting an indirect protective effect on platelet function.
No takes yet. Share an insight, caveat, or question.
May suggest antiplatelet effects of perindopril in hypertension; hypothesis-generating and should not change practice pending RCTs.
Okrucka et al. (1998) studied Essential hypertension (n=46). Perindopril vs. Baseline / Placebo was evaluated on Adrenaline-induced platelet aggregation (p=<0.02). Perindopril therapy for 1 month significantly decreased adrenaline-induced platelet aggregation in patients with essential hypertension compared to baseline (P<0.02).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: